(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 226.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.81%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Crinetics Pharmaceuticals's revenue in 2024 is $1,385,000.On average, 6 Wall Street analysts forecast CRNX's revenue for 2024 to be $137,901,356, with the lowest CRNX revenue forecast at $80,035,610, and the highest CRNX revenue forecast at $321,182,903. On average, 7 Wall Street analysts forecast CRNX's revenue for 2025 to be $1,353,082,023, with the lowest CRNX revenue forecast at $240,106,830, and the highest CRNX revenue forecast at $4,563,630,482.
In 2026, CRNX is forecast to generate $4,116,551,565 in revenue, with the lowest revenue forecast at $2,009,694,167 and the highest revenue forecast at $9,792,516,955.